ClinicalTrials.gg
Active, not recruitingNCT06538857Updated Oct 14, 2026

CEB-01 in Locally Resectable Pancreatic Cancer

An Early Phase 1 interventional study of Standard surgery and CEB-01 in Pancreatic Carcinoma, sponsored by CEBIOTEX. Active, not recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by CEBIOTEX · Early Phase 1, Interventional, and Treatment

Updated Oct 14, 2026Now Active, not recruitingPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies in Pancreatic Neoplasms with a site in Spain — 46 open to participants now, 70 under way, 11 of them phase 3. Pancreatic Neoplasms · Spain.

Planned enrollment
147th of 174
39 · median 146
Started
2024
with 15 others
Phase 1
35 of 202
5 open now
Primary completion
2028-09
later than 50 of 69 live
Registered
166th of 202
by date

Among the 202 studies in Pancreatic Neoplasms with a site in Spain, this one is the 147th largest by planned enrollment of the 174 interventional ones that give a count, is one of 16 that started in 2024, is one of 35 in phase 1, reaches primary completion later than 50 of the 69 other live ones, and was the 166th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

46 of the 202 studies in Pancreatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Pancreatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile.

The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer

Read the detailed description

Exploratory, multi-center, interventional, prospective, randomised, single-blind, controlled clinical trial in adult participants with locally resectable pancreatic cancer. Participants will be allocated in a 2:1 ratio to two treatment arms: (Arm 1, n=26 participants) standard surgery and CEB-01 implant after surgery, or (Arm 2, n=13 participants) standard surgery without implant. For measurement of primary safety and efficacy endpoints, follow-up will consist of shortterm evaluation at 365 ± 30 days and long-term evaluation at 1095 ± 30 days post-surgery as it is considered sufficient for the assessment of the therapeutic effect of CEB-01 regarding local recurrence. For pharmacokinetic assessment, blood samples will be collected at baseline and at 8 different time points until 60 ± 15 days post-surgery. For each participant the trial duration will be composed by a screening period for of up to 35 days, one day for surgery and 1095 ± 30 days of follow-up.

The trial population will consist of 39 participants with a de novo pancreatic cancer who fulfil all the inclusion and exclusion criteria.

03

Conditions studied

  • Pancreatic Carcinoma

Keywords

  • Locally advanced disease
  • Resectable pancreatic cancer
  • Borderline resectable pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Participants must have a diagnosis of:

    1. Lesion/s of or cytologically confirmed de novo carcinoma, adenocarcinoma or ductal adenocarcinoma of the pancreas with only locally advanced disease, resectable or borderline resectable.
    2. Histopathological confirmation of the diagnosis can be done during surgery by means of intraoperative as per clinical practice.

    No need of preoperative biopsy.

  3. Participants previously treated with chemotherapy will be eligible if they have not had documented progressive disease during treatment.
  4. Participants must have radiographically ; measurable disease is defined as the presence of at least one lesion obtained by a validate imaging technique (i.e., magnetic resonance imaging (MRI), computed tomography (CT) scan, PET scan, ultrasounds or others) that can be accurately measured.
  5. Participants should have surgically removable lesion/s for what they will be submitted to a pancreatoduodenectomy.
  6. Normal renal function as defined by biochemical parameters as follows: creatinine ≤2 mg/dl or ≥ 60 ml/min/1.73 m2.
  7. Haematological and cardiac function as defined by biochemical and haematological parameters as follows: (Hb) ≥10 g/dL (with preoperative transfusion), ≥80.000/mm3 with intraoperative transfusion, white blood cells (WBC) ≥3.000/mm3, ≥1.500/mm3.
  8. Liver function as defined by biochemical parameters as follows: (ALT) and aspartate aminotransferase (AST) ≤ 4 times the upper limit of normality []. Recommended serum for eligibility is bilirubin ≤ 10 mg/dl (or equivalent value in μmol/L units). Preoperative biliary drainage to be done according to regular practice in each center. Patients in whom preoperative biliary drainage cannot be performed or biliary drainage was not completely effective, individualized decision to be made when bilirubin is ≥ 10 mg/dl (or equivalent value in μmol/L units).
  9. Participants must have fully recovered from the acute toxic effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.
  10. chemotherapy is allowed in borderline and/or locally advanced cases borderline completed at least 4 weeks before surgery.
  11. (ECOG) Performance Status 0 or 1.
  12. Female subjects of must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
  13. Men and women of childbearing potential must be willing to use adequate throughout the study and for 6 months after surgery.
  14. The participant or a legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Other within past 2 years.
  2. R2 resections (macroscopic disease remains after surgery).
  3. Patients with homozygous UGT1A1 known to be at risk of increased toxicity with irinotecan and SN-38.
  4. Active bacterial, viral or fungal infection.
  5. Known history of active (HIV) infection, , or chronic liver disease. Testing is not required in the absence of clinical findings or suspicion.
  6. Impossibility of ensuring adequate follow-up.
  7. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  8. to computed tomography scan (CT).
  9. Major surgery within 14 days prior to starting study drug or still in recovery after experiencing surgical complications; neither tumour nor central line insertion are considered a major surgery.
  10. Other relevant concomitant illnesses.
  11. Participants' status post- stem cell transplant are not eligible.
  12. Participants with disease of any major organ system that would compromise their ability to withstand therapy.
  13. Pregnancy or lactation. Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Arm 1

    standard surgery and CEB-01 implant after surgery

    Procedure: Standard surgery · Drug: CEB-01

  • Active comparator
    Arm 2

    standard surgery

    Procedure: Standard surgery

Interventions

  • ProcedureStandard surgery

    The location and size of the tumor determine the type of surgery.

  • DrugCEB-01

    It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs) (Safety)

    Frequency of adverse events reported classified by type and severity according to the most updated version of the Common Terminology Criteria for Adverse Events (CTCAE v5.0). In addition to CTCAE, the severity of postoperative complications will also be graded according to Clavien-Dindo's classification (Clavien et al., 2009) and will be included in the assessment of AEs.

    Time frame: Through study completion, average 3 years

  2. Frequency of surgical complications after pancreatic surgery

    Frequency of surgical complications according to the International Patient Safety Goals (IPSG).

    Time frame: Through study completion, after surgery average 3 years

Secondary outcomes

  1. Local recurrence-free survival (LRFS)

    Time from surgery until the progression of the disease in the area of implanted CEB-01

    Time frame: Through study completion, average 3 years

  2. Progression-free survival (PFS)

    Time from surgery to objective tumour progression or death from any cause

    Time frame: Through study completion, average 3 years

  3. Overall survival (OS)

    Time from surgery to death from any cause

    Time frame: Through study completion, average 3 years

  4. Maximum concentration (Cmax) of SN-38

    The highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints

    Time frame: During 60 days

  5. Time of maximum plasma concentration (Tmax) of SN-38

    Time from the surgery to the momento with the highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints

    Time frame: During 60 days

  6. Terminal half-life (t1/2) of SN-38

    The time required for the plasma concentration of SN-38 to fall by 50% from the Cmax

    Time frame: During 60 days

  7. Area under the concentration-time curve (AUC0-inf) of SN-38

    Represents the total SN-38 exposure in the peripheral blood across time

    Time frame: During 60 days

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No — No individual participant data (IPD) will be provided.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2028, 49 months after the start.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 49 months is above that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 6, 2024
StartActual
Aug 20, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 Spain)
  • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
  • H. Clínico San Carlos · Madrid, Spain
  • H.U. Virgen del Rocío · Seville, Spain
  • H. Clínico Univ. de Valencia · Valencia, Spain
Show 4 removed
  • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
  • H. Clínico San Carlos · Madrid, Spain
  • H.U. Virgen del Rocío · Sevilla, Spain
  • H. Clínico Univ. de Valencia · Valencia, Spain
Oct 5, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionFrequency of Adverse Events (AEs) (Safety): how it is measured was reworded
Oct 5, 2026
Design
Phase 2→Early Phase 1
Oct 5, 2026
Show all 2 updates
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 5, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Spain)
    • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
    • H. Clínico San Carlos · Madrid, Spain
    • H.U. Virgen del Rocío · Seville, Spain
    • H. Clínico Univ. de Valencia · Valencia, Spain
    Show 4 removed
    • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
    • H. Clínico San Carlos · Madrid, Spain
    • H.U. Virgen del Rocío · Sevilla, Spain
    • H. Clínico Univ. de Valencia · Valencia, Spain
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionFrequency of Adverse Events (AEs) (Safety): how it is measured was reworded
    Design Phase 2→Early Phase 1
    + 4 other changes: verification date, oversight details, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06538857
Lead sponsor
CEBIOTEX
Collaborators
MFAR
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Aug 20, 2024
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Javier Padillo Ruiz, M.D.; Ph.D.
principal investigator · H.U. Virgen del Rocío (Sevilla)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CEB-01

Start the discussion